ARA-290 vs GHRP-2
Side-by-side comparison of key properties, dosing, and research.
- Summary
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- GHRP-2 is a potent synthetic hexapeptide that stimulates growth hormone release by activating ghrelin receptors in the pituitary and hypothalamus. It produces one of the strongest GH pulses among GHRPs, though unlike Ipamorelin it does cause modest increases in cortisol and prolactin.
- Half-Life
- ~2–4 hours (SC administration)
- 15–60 minutes
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 4 mg (fixed dose)
- 100–300 mcg
- Frequency
- Once daily
- 2–3 times daily
- Key Benefits
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Strong GH pulse stimulation
- Increased IGF-1 levels
- Enhanced muscle growth and recovery
- Improved fat metabolism
- Better sleep quality
- Increased bone density
- Enhanced appetite (less pronounced than GHRP-6)
- Anti-aging effects via GH axis optimization
- Side Effects
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Increased appetite
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Stacks With
- —
- —